<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512863</url>
  </required_header>
  <id_info>
    <org_study_id>M05-757</org_study_id>
    <nct_id>NCT00512863</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma</brief_title>
  <official_title>A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of SC injections of 3 regimens of adalimumab vs. placebo in the&#xD;
      change in post-bronchodilator FEV1 from Baseline to Week 16 when used in the treatment of&#xD;
      refractory asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the change from Baseline in post-bronchodilator FEV1 in subjects treated with adalimumab vs. placebo.</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one asthma exacerbation from Baseline to the end of the double-blind period</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in post-bronchodilator FEV1</measure>
    <time_frame>Time points other thanWeek 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pre-bronchodilator FEV1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (pre-bronchodilator) in FEV1</measure>
    <time_frame>30 minutes postbronchodilator</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in percent predicted FEV1</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humira (adalimumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented history of refractory asthma, as defined by the American Thoracic&#xD;
             Society,31 defined as 1 major and at least 2 minor criteria&#xD;
&#xD;
          -  Actual or documented history of reversible airway obstruction&#xD;
&#xD;
          -  Baseline FEV1 of 40% - 80% of the predicted for height, age, and sex at Screening, as&#xD;
             demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours&#xD;
             after a long-acting -agonist&#xD;
&#xD;
          -  History of at least 1 asthma exacerbation leading to oral, IV or IM corticosteroid or&#xD;
             ER/Urgent Care Center visit or hospitalization within the past year prior to&#xD;
             Screening. This asthma exacerbation should not have been within 30 days prior to&#xD;
             Screening&#xD;
&#xD;
          -  Adequate cardiac, renal and hepatic function as determined by the principal&#xD;
             investigator and demonstrated by Screening laboratory evaluations, questionnaires, and&#xD;
             physical examination results that are within normal limits&#xD;
&#xD;
          -  Subjects must be able to self-inject study medication or have a designee or healthcare&#xD;
             professional who can inject the study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [COPD],&#xD;
             interstitial lung disease, pulmonary fibrosis) other than asthma&#xD;
&#xD;
          -  Current treatment for corticosteroid-resistant asthma (e.g., methotrexate [MTX],&#xD;
             cyclosporine, gold salts, troleandomycin, immune globulin intravenous [IGIV],&#xD;
             mycophenolate mofetil)&#xD;
&#xD;
          -  History of cancer or lymphoproliferative disease other than a successfully and&#xD;
             completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma -&#xD;
             in-situ of the cervix.&#xD;
&#xD;
          -  History of listeria, human immunodeficiency virus (HIV), chronic or active Hepatitis&#xD;
             B, an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease or&#xD;
             active TB&#xD;
&#xD;
          -  Females who are pregnant or will not discontinue breast-feeding.&#xD;
&#xD;
          -  Subject with a history of clinically significant drug or alcohol abuse in the last&#xD;
             year&#xD;
&#xD;
          -  Subjects with a poorly controlled medical condition.&#xD;
&#xD;
          -  Abnormal, clinically significant screening laboratory and other analyses (including&#xD;
             ECG).&#xD;
&#xD;
          -  Subjects with any prior exposure to TysabriÂ® (natalizumab)&#xD;
&#xD;
          -  Prior treatment with any TNF antagonist, including adalimumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Paperiello</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>November 5, 2007</last_update_submitted>
  <last_update_submitted_qc>November 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

